C4 Therapeutics (CCCC) director awarded 62,000 stock options at $4.25 strike
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
C4 Therapeutics director Laura Bessen received a new stock option grant covering 62,000 shares of common stock. The option has an exercise price of $4.25 per share and expires on June 23, 2036. This is a compensation-related award, not an open‑market trade.
According to the terms, the option vests and becomes fully exercisable on the earlier of June 24, 2027 or the company’s next annual stockholder meeting, as long as Bessen continues serving on the board through that date. After this grant, she holds 62,000 derivative securities directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Bessen Laura
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 62,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 62,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 62,000 options
Exercise price: $4.25 per share
Expiration date: June 23, 2036
+3 more
6 metrics
Option grant size
62,000 options
Stock Option (Right to Buy) covering common stock
Exercise price
$4.25 per share
Exercise price of the stock option grant
Expiration date
June 23, 2036
Option expiration for the 62,000-share grant
Vesting date
June 24, 2027
Latest vesting date, or earlier at next annual meeting
Shares underlying option
62,000 shares
Underlying C4 Therapeutics common stock
Post-transaction holdings
62,000 derivative securities
Total options held directly after grant
Key Terms
Stock Option (Right to Buy), Grant, award, or other acquisition, exercise price, expiration date, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
exercise price financial
"conversion_or_exercise_price: 4.2500"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-23T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest and become exercisable financial
"This option shall vest and become exercisable in full upon the earlier"
FAQ
What did C4 Therapeutics (CCCC) director Laura Bessen receive in this Form 4?
Laura Bessen received a stock option grant for 62,000 shares of C4 Therapeutics common stock. The award is a compensation-related option, not a market purchase, and gives her the right to buy shares at a fixed exercise price in the future.
What is the exercise price and term of Laura Bessen’s C4 Therapeutics option grant?
The option has an exercise price of $4.25 per share and expires on June 23, 2036. This long-term term allows significant time for potential exercise if vesting conditions are met and Bessen chooses to convert the option into common shares.
When do Laura Bessen’s C4 Therapeutics options vest according to the Form 4?
The option vests and becomes exercisable in full on the earlier of June 24, 2027, or the next annual meeting of C4 Therapeutics stockholders. Vesting also requires her continued service on the company’s board through the applicable vesting date.
Is Laura Bessen buying or selling C4 Therapeutics stock in this Form 4 filing?
She is not buying or selling shares in the open market. The Form 4 reports a grant of 62,000 stock options as compensation, which is classified as an acquisition of derivative securities rather than a purchase or sale of existing common shares.
How many C4 Therapeutics derivative securities does Laura Bessen hold after this transaction?
Following the reported grant, Bessen holds 62,000 derivative securities related to C4 Therapeutics common stock. These represent options rather than currently owned shares and are exercisable only after the specified vesting conditions are satisfied in the future.